Parkinson's Drug Nuplazid Priced High; Acadia Aims For Alzheimer's Next
Executive Summary
Acadia Pharmaceuticals Inc. priced its Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin) at $1,950 for a 30-day supply, which was significantly higher than Wall Street expected. With the US approval of Nuplazid in PDP in hand, the company is now focused on its development programs for the drug as a treatment for Alzheimer's disease psychosis and Alzheimer's agitation.